#### **CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL-CELL LUNG CANCER TREATED WITH** NIVOLUMAB




A. Codonal Demetrio, I. Mendoza Acosta, M. Blanco Crespo, GI. Casarrubios Lázaro, E. Martínez, P. Tardáguila Molina, A. Miranda del Cerro, LE. Chara Velarde, P. De Juán-García Torres. Hospital Pharmacy, Hospital Emergency Department. Guadalajara, Spain.

## **BACKGROUND AND IMPORTANCE**

Nivolumab, an immune checkpoint inhibitor, has shown a relationship between immune-related adverse events (irAEs) and efficacy in different studies, although these are not very consistent.

# **AIM AND OBJECTIVES**



## **MATERIALS AND METHODS**

**Restrospective observational study** 

August 2015- June 2022

Anti-PD-L

Anti-

✓ **Data collected:** demographic (age, sex) and clinical (histology, smoking habit, performance status) (ECOG), line of treatment, response to previous chemotherapy and irAEs).

✓ Overall survival (OS) and progression-free survival (PFS) analysis was performed using Kaplan Meier. The association between irAEs and OS were analyzed by Cox Regression.

#### RESULTS



• 67 patients (88% men) Median age at the beginning of treatment: 67 years (IQR: 59-75)

**DECOG 0-1: 52%** 

□Second line treatment: 73%

□Histology squamous: 40%

Disease Control Rate: 78%


□Former smorkers/Smokers/Nonsmokers: 53%/39%/8%

irAEs type	N=28 irAEs (22 patients)	HR (95% CI)	р
Pneumonitis	10	0.62 (0.3-1.3)	0.2
Endocrine	6	0.23 (0.1-0.7)	0.014
Gastrointestinal	6	0.59 (0.2-1.6)	0.3
Skin	6	0.2 (0.1-0.7)	0.008

### **CONCLUSION AND RELEVANCE**

 $\checkmark$ In this study our data suggest a relationship between irAEs and increased OS, specially endocrine and skin.  $\checkmark$  As our study was observational, other features as sex, ECOG or smoking habit that could bias results were not balanced between the study groups.

	irAE	Non-irAE
<b>OS</b> (months) (95% Cl; p<0,05)	<b>12.1</b> (7.9-16.3)	<b>4.4</b> (1.9-7.0)
<b>PFS</b> (months) (95% Cl; p<0,05)	<b>8.7</b> (0-41.2)	<b>3.3</b> (1.9-4.7)







AT REALLY MATTERS